LifeVantage(LFVN) - 2026 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q2 of fiscal 2026, net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 of fiscal 2025, but up 2.9% sequentially from Q1 [14] - The decline was primarily driven by a $16.2 million decrease in sales of the MindBody GLP-1 System, partially offset by $4.1 million in revenue from the LoveBiome product line [14] - Gross profit percentage decreased to 74% from 80.5% in the prior year, reflecting a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System significantly declined due to increased competition from pharmaceutical options, which are now more accessible and affordable [5][6] - The LoveBiome acquisition contributed $4.1 million in revenue, with two new products launched that are expected to drive engagement and growth [8][9] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while revenue in Asia-Pacific and Europe decreased 2.1% to $10.4 million [15] - The Americas decline was attributed to a 25.2% decrease in total active accounts, primarily from the customer base [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities to maintain profitability [7] - Continued integration of LoveBiome is expected to enhance product diversification and market growth [8] - The company is optimistic about its comprehensive wellness ecosystem, which includes various health products [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but remains confident in long-term growth potential [4] - The company anticipates revenue in the range of $185 million to $200 million for fiscal 2026, with adjusted EBITDA of $15 million to $19 million [19] Other Important Information - A new $60 million share repurchase program was announced, replacing the previous program [18] - A quarterly cash dividend of $0.045 per share was declared, to be paid on March 16, 2026 [19] Q&A Session Summary Question: About LoveBiome transaction costs - The $3.7 million cash at closing was the actual purchase price for LoveBiome, structured in two components: cash down payment and future earnout based on revenue targets [23] Question: Update on MindBody marketing plans - A 20% discount promotion was initiated, along with an "Activate90" event for holistic health discussions and a new app feature for tracking health activities [26][27][28] Question: Revenue split expectations for the second half of the year - Management expects stabilization in MindBody trends and anticipates Q4 will likely have a higher proportion of revenue compared to Q3 [51][53]